Key result
Moxonidine (6 mg/kg/d) completely prevented MI-induced concentric hypertrophy and restored capillary density, thereby improving ischemic tolerance in infarcted rats.
Why the study?
Does moxonidine prevent left ventricular hypertrophy and improve ischemic tolerance in infarcted rats?
Population
Infarcted rats
Comparison
Moxonidine 3 or 6 mg/kg/d from 1 to 21 days… vs Untreated infarcted rats and sham rats
Design
Preclinical, randomized
Follow-up
21 days
Authors
Loading...
Hypothesis-generating in post-MI remodeling; leaves open translation of hypertrophy and capillary effects to human therapy.
RCT
Randomized
Does moxonidine prevent left ventricular hypertrophy and improve ischemic tolerance in infarcted rats?
In a rat model of myocardial infarction, moxonidine prevented left ventricular hypertrophy and preserved capillary density, thereby improving the ischemic tolerance of the spared myocardium.
Kerckhoven et al. (2002) conducted an RCT in Myocardial infarction. Moxonidine vs. Sham/control was evaluated on Left ventricular hypertrophy and capillary density. Moxonidine (6 mg/kg/d) completely prevented MI-induced concentric hypertrophy and restored capillary density, thereby improving ischemic tolerance in infarcted rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: